Reversible cerebral vasoconstriction syndrome associated with fingolimod treatment in relapsing-remitting multiple

Markus Kraemer1, Ralph Weber2, Michèle Herold2

  • 1Department of Neurology, Alfried Krupp Hospital, Essen, Germany markus.kraemer@krupp-krankenhaus.de.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|August 19, 2015
PubMed

Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by acute thunderclap headache, evidence of vasoconstriction in conventional angiography or magnetic resonance angiography and reversibility of these phenomena within 12 weeks. Some triggering factors, for example drugs such as selective serotonin reuptake inhibitors, sumatriptan, tacrolimus, cyclophosphamide and cocaine, or states such as pregnancy, puerperium or migraine have been described. We describe the case of a 29-year-old woman with RCVS associated with fingolimod three months after childbirth. This case represents the first report of RCVS in fingolimod treatment.

Related Concept Videos